PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
April 16, 2024 08:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, provides an update of its...
PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome
November 01, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on developing and...
PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX™ Ketamine Patch
September 07, 2022 07:00 ET
|
PharmaTher Holdings Ltd.
KETARX™ Ketamine Patch demonstrated extended delivery of ketamine over 40 hours KETARX™ Ketamine Patch offers flexible dosing through increased size, drug load or concentration of ketamine to better...
PharmaTher Announces CAD$10 Million Private Placement With Institutional Investors
September 24, 2021 08:00 ET
|
PharmaTher Holdings Ltd.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 24, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE:...
PharmaTher To Participate in Grizzle Psychedelics Con
June 28, 2021 08:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, June 28, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that...